TLR7 and neoplasm: Another TLR7 agonist, 852A was found to stimulate plasmacytoid DCs to produce IFN type I and activate both CD8+ T cells and NK cells resulting in anti-tumor response (Inglefield et al. 2008; Weigel et al. 2012).